1-5 of 5
Lian-Chun Xiao
Close
Sort by
Journal Articles

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Sai Prasad Desikan, Marina Konopleva, Koichi Takahashi, Curtis A Lachowiez, Sanam Loghavi, Lian-Chun Xiao, Tapan M. Kadia, Naval Daver, Nicholas Short, Koji Sasaki, Gautam Borthakur, Ghayas C. Issa, Abhishek Maiti, Kelly S. Chien, Yesid Alvarado, Guillermo Montalban-Bravo, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Guillermo Garcia-Manero, Steven M. Kornblau, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 534–536.
https://doi.org/10.1182/blood-2022-164922
Published: 2022
Journal Articles

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

Curtis Lachowiez, Courtney D. DiNardo, Koichi Takahashi, Sanam Loghavi, Lian-Chun Xiao, Tapan M. Kadia, Naval Daver, Maria Adeoti, Nicholas J. Short, Koji Sasaki, Sa A Wang, Gautam Borthakur, Ghayas C. Issa, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Guillermo Montalban-Bravo, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Guillermo Garcia-Manero, Steven M. Kornblau, Farhad Ravandi, Elias J. Jabbour, Marina Konopleva, Hagop Kantarjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 701.
https://doi.org/10.1182/blood-2021-150457
Published: 2021
Journal Articles

Determinants of Outcomes of FLT3 mut Acute Myeloid Leukemia with First Salvage Therapy

Abhishek Maiti, MBBS, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Srdan Verstovsek, MD PhD, Michael Andreeff, MD PhD, Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MDMSc, Sherry A. Pierce, BSN, BA, Lian-Chun Xiao, Xuelin Huang, PhD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2641.
https://doi.org/10.1182/blood-2019-129621
Published: 2019
Journal Articles

Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality

Gautam Borthakur, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Elias J. Jabbour, MD, Tapan Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Maro Ohanian, DO, William G Wierda, MD PhD, Nitin Jain, MD, Lian-Chun Xiao, Paromita Mukherjee, Mark Brandt, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 892.
https://doi.org/10.1182/blood.V130.Suppl_1.892.892
Published: 2017
Journal Articles

Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity

Patrick Williams, MD PhD, Sreyashi Basu, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Zainab Al-Hamal, Marina Konopleva, MD PhD, Jing Ning, PhD, Lian-Chun Xiao, Juliana Hidalgo Lopez, Steven Kornblau, MD, Michael Andreeff, MD PhD, Wilmer Flores, Carlos E. Bueso-Ramos, MD PhD, Narmeen Somani, Jorge Blando, Gheath Alatrash, DO, PhD, James P Allison, Hagop M. Kantarjian, MD, Padmanee Sharma, MD PhD, Naval Daver, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 185.
https://doi.org/10.1182/blood.V130.Suppl_1.185.185
Published: 2017